Clinical Decision-Making for Obinutuzumab in Glomerular Disease

Authored by Sourabh Sharma, published on 2026-11-16 12:10:10.0

  1. Confirm Active Disease and Quantify Baseline Kidney Activity
    • Active Immune Disease Likely to Benefit From B-Cell Depletion?
      • Check HBV, CBC, Immunoglobulins, Infection, and Vaccination Status
        • Contraindication or Unresolved Safety Barrier?
          • Do Not Initiate Obinutuzumab; Treat Barrier or Redirect
          • Classify Glomerular Disease and Evidence Status
            • Adult Primary MN at Risk of Progression?
              • MAJESTY: Give 1,000 mg IV Weeks 0, 2, 24, 26
                • Premedicate and Infuse With Emergency Reaction Capability
                  • Monitor CBC, IgG, CD19, Proteinuria, eGFR, and Disease Serologies
                    • Serious Treatment Toxicity or Severe Hypogammaglobulinemia?
                      • Permanently Stop Obinutuzumab and Use Alternative Therapy
                      • Hold Therapy; Treat Complication and Reassess Resumption
                      • Classify Clinical Response Before Isolated Serologic Response
                        • Continue Scheduled Therapy or Maintenance Protocol
                        • Allow Clinical Response Lag; Evaluate Chronic Kidney Damage
                        • Reassess Benefit-Risk and Use Disease-Specific Retreatment
                        • Reassess Diagnosis and Scarring; Switch Mechanism or Enroll Trial
              • Do Not Initiate Obinutuzumab; Treat Barrier or Redirect
            • Adult Active LN Receiving Standard Therapy?
              • REGENCY: Give 1,000 mg IV Weeks 0, 2, 24, 26, Then Every 6 Months
                • Premedicate and Infuse With Emergency Reaction Capability
                  • Monitor CBC, IgG, CD19, Proteinuria, eGFR, and Disease Serologies
                    • Serious Treatment Toxicity or Severe Hypogammaglobulinemia?
                      • Permanently Stop Obinutuzumab and Use Alternative Therapy
                      • Hold Therapy; Treat Complication and Reassess Resumption
                      • Classify Clinical Response Before Isolated Serologic Response
                        • Continue Scheduled Therapy or Maintenance Protocol
                        • Allow Clinical Response Lag; Evaluate Chronic Kidney Damage
                        • Reassess Benefit-Risk and Use Disease-Specific Retreatment
                        • Reassess Diagnosis and Scarring; Switch Mechanism or Enroll Trial
              • Do Not Initiate Obinutuzumab; Treat Barrier or Redirect
            • Refractory, Relapsing, or Rituximab-Intolerant AAV?
              • Off-Label AAV: 1,000 mg IV Once or Weeks 0 and 2
                • Premedicate and Infuse With Emergency Reaction Capability
                  • Monitor CBC, IgG, CD19, Proteinuria, eGFR, and Disease Serologies
                    • Serious Treatment Toxicity or Severe Hypogammaglobulinemia?
                      • Permanently Stop Obinutuzumab and Use Alternative Therapy
                      • Hold Therapy; Treat Complication and Reassess Resumption
                      • Classify Clinical Response Before Isolated Serologic Response
                        • Continue Scheduled Therapy or Maintenance Protocol
                        • Allow Clinical Response Lag; Evaluate Chronic Kidney Damage
                        • Reassess Benefit-Risk and Use Disease-Specific Retreatment
                        • Reassess Diagnosis and Scarring; Switch Mechanism or Enroll Trial
              • Do Not Initiate Obinutuzumab; Treat Barrier or Redirect
            • Age ≥2 With Childhood-Onset FRNS or SDNS in Complete Remission?
              • INSHORE: ≥45 kg 1,000 mg; <45 kg 20 mg/kg at Weeks 0, 2, 24, 26
                • Premedicate and Infuse With Emergency Reaction Capability
                  • Monitor CBC, IgG, CD19, Proteinuria, eGFR, and Disease Serologies
                    • Serious Treatment Toxicity or Severe Hypogammaglobulinemia?
                      • Permanently Stop Obinutuzumab and Use Alternative Therapy
                      • Hold Therapy; Treat Complication and Reassess Resumption
                      • Classify Clinical Response Before Isolated Serologic Response
                        • Continue Scheduled Therapy or Maintenance Protocol
                        • Allow Clinical Response Lag; Evaluate Chronic Kidney Damage
                        • Reassess Benefit-Risk and Use Disease-Specific Retreatment
                        • Reassess Diagnosis and Scarring; Switch Mechanism or Enroll Trial
              • Do Not Initiate Obinutuzumab; Treat Barrier or Redirect
            • MCD, Cryoglobulinemic GN, or Other Emerging Disease?
              • Off-Label: Use Disease-Specific Published or Trial Protocol
                • Premedicate and Infuse With Emergency Reaction Capability
                  • Monitor CBC, IgG, CD19, Proteinuria, eGFR, and Disease Serologies
                    • Serious Treatment Toxicity or Severe Hypogammaglobulinemia?
                      • Permanently Stop Obinutuzumab and Use Alternative Therapy
                      • Hold Therapy; Treat Complication and Reassess Resumption
                      • Classify Clinical Response Before Isolated Serologic Response
                        • Continue Scheduled Therapy or Maintenance Protocol
                        • Allow Clinical Response Lag; Evaluate Chronic Kidney Damage
                        • Reassess Benefit-Risk and Use Disease-Specific Retreatment
                        • Reassess Diagnosis and Scarring; Switch Mechanism or Enroll Trial
              • Do Not Initiate Obinutuzumab; Treat Barrier or Redirect
      • Do Not Initiate Obinutuzumab; Treat Barrier or Redirect
tosprivacy